Gilead Sciences (GILD) Cash & Equivalents (2009 - 2026)

Gilead Sciences (GILD) has reported Cash & Equivalents for 18 consecutive years, with $3.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 38.2% year-over-year to $3.2 billion; the trailing twelve-month figure through Jun 2026 stood at $3.2 billion (down 38.2% YoY), and the FY2025 full-year result was $7.6 billion, down 24.29% from the prior year.
• Cash & Equivalents eased to $3.2 billion in Q2 2026 per GILD's latest filing, from $7.6 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $10.0 billion in Q4 2024 and bottomed at $2.8 billion in Q2 2024.
• Historically, Cash & Equivalents has averaged $5.7 billion across 5 years, with a median of $5.3 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 51.4% in 2024, then soared 85.57% in 2025.
• Over 5 years, Cash & Equivalents stood at $5.4 billion in 2022, then increased by 12.44% to $6.1 billion in 2023, then surged by 64.19% to $10.0 billion in 2024, then slipped by 24.29% to $7.6 billion in 2025, then tumbled by 57.97% to $3.2 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.2 billion, $7.6 billion, and $7.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.